Comprehensive Preclinical Consulting
At Imp-Path Consulting, we excel in preclinical consulting, providing unmatched expertise and support for the medical device industry. Our services are meticulously crafted to drive strategic growth and foster innovation for both emerging and established companies.
M&A – Due Diligence
We conduct comprehensive reviews of preclinical data, with a focus on pathology data within the broader context of biological response characterization. This service benefits companies looking to position their intellectual property for acquisitions or those seeking to acquire new technology.
Alongside early clinical and in vivo preclinical data, preclinical histopathology is a cornerstone in evaluating the safety, healing, and integration profile of any implant within a live test system. Preclinical pathology data are often the least digestible and most challenging to interpret, yet they remain crucial for assessing and predicting risks in clinical settings. Imp-Path Consulting was established to help companies fill a critical gap in merger and acquisition risk assessment, enabling informed decision-making through the full potential of preclinical data packages.
Counsel in Preclinical Development Strategy
Imp-Path Consulting reviews your preclinical data within the context of the current regulatory framework, providing recommendations based on best practices in preclinical studies for medical device assessment. We also evaluate your entire preclinical data to identify potential gaps and blind spots, ensuring a robust dataset presentation to investors or prospective partners.
Expertise in Medical Device and Implant Histopathology
These services form the core of our practice and are delivered through our affiliation with StageBio, Inc.